Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis

Russell, I. Jon; Værøy, Henning; Javors, Martin A.; Nyberg, Fred

doi:10.1002/art.1780350509

Cited by 480 publications

(260 citation statements)

References 31 publications

Supporting

Mentioning

230

Contrasting

Unclassified

Order By: Relevance

“…For example, low levels of biogenic amines (22) and high levels of substance P (23) have been found in the cerebrospinal fluid in FM. Abnormalities in imipramine uptake receptors have also been noted (24).…”

Section: Discussionmentioning

confidence: 99%

A randomized, double‐blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia

Goldenberg

Mayskiy

Mossey

et al. 1996

Arthritis & Rheumatism

375

190

View full text Add to dashboard Cite

Objective. To study the effect of fluoxetine (FL) and amitriptyline (AM), alone and in combination, in patients with fibromyalgia (FM).Methods. Nineteen patients with FM completed a randomized, double-blind crossover study, which consisted of 4 6-week trials of FL (20 mg), AM (25 mg), a combination of FL and AM, or placebo. Patients were evaluated on the first and last day of each trial period. Outcome measures included a tender point score, the Fibromyalgia Impact Questionnaire (FIQ), the Beck Depression Inventory (BDI) scale, and visual analog scales PAS) for global well-being (1 completed by the physican and 1 by the patient), pain, sleep trouble, fatigue, and feeling refreshed upon awakening.Results. Both FL and AM were associated with significantly improved scores on the FIQ and on the VAS €or pain, global well-being, and sleep disturbances. When combined, the 2 treatments worked better than either medication alone. Similar, but nonsignificant, improvement occurred in the BDI scale, the physician global VAS, and the VAS for fatigue and feeling refreshed upon awakening. Trends were less clear for the tender point score.Conclusion. Both FL and AM are effective treatments for FM, and they work better in combination than either medication alone.Clinical trials of medications for the treatment of fibromyalgia (FM) have demonstrated modest or little efficacy. Tricyclic and tetracyclic "antidepressant" drugs

show abstract

Section: Discussionmentioning

confidence: 99%

A randomized, double‐blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia

Goldenberg

Mayskiy

Mossey

et al. 1996

Arthritis & Rheumatism

375

190

View full text Add to dashboard Cite

show abstract

“…Studies have shown that patients with fibromyalgia have reduced levels of biogenic amine metabolites, including dopamine, norepinephrine, and serotonin, in their cerebrospinal fluid [6,7]. It has been suggested that decreased iron stores lead to a reduced production of biogenic amines since iron is essential for neurotransmitter synthesis [8].…”

Section: Fibromyalgia Is a Disorder Characterized By Chronic Widesprementioning

confidence: 99%

A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia

Boomershine

Koch²,

Morris³

2017

Rheumatol Ther

View full text Add to dashboard Cite

Introduction: This study sought to compare efficacy and safety of ferric carboxymaltose vs. placebo in iron-deficient patients with fibromyalgia. Methods: This blinded, placebo-controlled, phase 2 study randomized adults with fibromyalgia and Revised Fibromyalgia Impact Questionnaire (FIQR) scores C 60, ferritin levels \0.05 lg/ml, and transferrin saturation \20% (1:1) to receive ferric carboxymaltose [15 mg/kg (up to 750 mg)], or placebo (15 cc normal saline) intravenously on study days 0 and 5. Patients visited the clinic on days 14, 28, and 42 for efficacy and safety assessments. The primary efficacy endpoint was proportion of patients with a C 13-point improvement from baseline to day 42 in FIQR scale score. Secondary endpoints included changes from baseline in FIQR scale, Brief Pain Inventory (BPI) total score, Medical

show abstract

“…Animal models suggest that depletion of monoaminergic neurotransmitters in the spinal cord, thalamus, and prefrontal cortex can cause chronic muscular pain, hyperalgesia, allodynia, and depression, which can be attenuated by treatment with serotonin and norepinephrine reuptake inhibitors (SNRIs) or pregabalin (11). Human studies confirm that patients with fibromyalgia have lowered levels of monoamines (12) in their cerebrospinal fluid and higher levels of substance P (13) and nerve growth factor (14). Serotonin and norepinephrine are thought to be the key neurotransmitters in the descending pain inhibitory system, and dopamine also appears to be involved in pain control in the central nervous system (15,16).…”

mentioning

confidence: 99%

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

McIntyre

Paisley

Kouassi

et al. 2014

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. Fibromyalgia and major depressive disorder (MDD) frequently co-occur. Quetiapine fumarate extended-release (quetiapine XR) has demonstrated efficacy in the treatment of MDD and has been shown to have analgesic properties in patients with depression. The primary objectives of this study were to evaluate the effects of quetiapine XR on depressive and pain symptoms in patients with MDD and comorbid fibromyalgia, and to assess its safety and tolerability. Results. The mean change in the HAM-D score from baseline to week 8 was significantly greater in the quetiapine XR group compared with the placebo group (؊10.0 versus ؊5.8; P ‫؍‬ 0.001). Improvements in most secondary outcomes were also significantly greater in the quetiapine XR group. Quetiapine XR was generally well tolerated.Conclusion. This study is the first to demonstrate that measures of depression, pain, and quality of life are significantly improved with quetiapine XR compared with placebo in patients with a dual diagnosis of MDD and fibromyalgia.Fibromyalgia is a syndrome characterized by widespread musculoskeletal pain that lasts at least 3 months, with a reduced pain threshold. Widespread pain is the defining feature of fibromyalgia. Associated symptoms include fatigue, sleep disturbance, stiffness, cognitive symptoms, and mood abnormalities including depression and anxiety (1,2). Pain, fatigue, and sleep disturbance are present in at least 75% of patients (3). The condition is estimated to occur in ϳ2-4% of the general adult population (4,5), and the prevalence is higher among women (4.9%) than men (1.6%) (6).Patients with fibromyalgia are at increased risk of mood disorders. Studies suggest that the prevalence of current depression among patients with fibromyalgia is as high as 22-40% (7), and that lifetime prevalence rates reach 58-86% (8,9). This high degree of co-occurrence is thought to be related in part to pathophysiologic abnormalities that are shared between fibroClinicalTrials.gov identifier: NCT00675896.

show abstract

Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis

Cited by 480 publications

References 31 publications

A randomized, double‐blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia

A randomized, double‐blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia

A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Ferric Carboxymaltose in Iron-Deficient Patients with Fibromyalgia

Quetiapine Fumarate Extended‐Release for the Treatment of Major Depression With Comorbid Fibromyalgia Syndrome: A Double‐Blind, Randomized, Placebo‐Controlled Study

Contact Info

Product

Resources

About